Lorlatinib
Brand: Lorbrena (global)
Anticancer
ALK inhibitor (3rd gen)
Pharmacokinetics
| Half-life | 24 hours |
| Tmax | 2 h |
| Protein Binding | 66 % |
| Volume of Distribution | 305 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | High CNS penetration; substrate of CYP3A & also a moderate CYP3A inducer. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Cognitive/mood changes, hyperlipidemia, neuropathy, edema, weight gain
Contraindications:
Severe uncontrolled hyperlipidemia
Precautions:
Monitor lipids regularly; psychiatric symptom screening advised during therapy.
t1/2 ≈ 24 hours → 1 day
dose typical 100 mg/day